Flynn James P purchased $22K of LITS
Flynn James P purchased 27,450 shares of Lite Strategy, Inc. (LITS) at $0.78 on 2026-11-17.
Lite Strategy, Inc.
Lite Strategy is a pharmaceutical company developing voruciclib and zandelisib, drug candidates that it is evaluating for potential nononcologic uses or out-licensing and sale. Voruciclib is an oral CDK9 inhibitor in preclinical development for nononcologic diseases. Zandelisib is an oral, once-daily selective PI3Kδ inhibitor; Lite Strategy is not conducting clinical trials for it and is assessing out-licensing or sale opportunities. The company sold ME-344, a mitochondrial inhibitor, to Aardvark Therapeutics, Inc. in October 2024. Lite Strategy also holds Litecoin tokens as a primary reserve asset. It writes covered call options on some holdings through contracts with GSR Markets Ltd, a strategy intended to generate liquidity and income while retaining exposure to the assets. It is headquartered in San Diego, California.
No enriched coverage for $LITS in the last 7 days.
Flynn James P purchased 27,450 shares of Lite Strategy, Inc. (LITS) at $0.78 on 2026-11-17.
Lite Strategy (LITS) reported Q1 results, showing a 52% reduction in cash used for operations and a 24% decrease in G&A expenses year-over-year. The company held $4.3M in cash, $46.2M in digital assets, with total assets of $58.4M and liabilities of $1.7M, according to the press release.
Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed
Recent LITS coverage spans earnings, insider activity and corporate actions.
In the last 30 days, LITS insiders filed 1 SEC Form 4 transaction — 1 purchase ($22K) and no sales. The most active reporter was Flynn James P with 1 filing.
Small insider purchase signals confidence but limited material impact.
Lower cash burn and expense reduction improve cost efficiency, likely supporting short-term price upside.
The cashless exercise adds ~517k shares, modestly diluting existing shareholders.
Small insider purchase may signal modest confidence but unlikely to move price.
Earnings are highly sensitive to Litecoin price movements and the company's treasury strategy.
AlphAI scores every news story that mentions LITS with an AI model for sentiment and relevance, and aggregates insider trades from Lite Strategy, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Flynn James P purchased 27,450 shares of Lite Strategy, Inc. (LITS) at $0.78 on 2026-11-17.
Lite Strategy (LITS) reported Q1 results, showing a 52% reduction in cash used for operations and a 24% decrease in G&A expenses year-over-year. The company held $4.3M in cash, $46.2M in digital assets, with total assets of $58.4M and liabilities of $1.7M, according to the press release.
Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. As previously reported, on July 22, 2025, Lite Strategy, Inc. (the “Company”) entered into an Advisory Agreement (the “Advisory Agreement”) with Green Dragon Investments LLC (“Green Dragon”), pursuant to which the Company agreed
Glover Nicholas purchased 2,000 shares of Lite Strategy, Inc. (LITS) at an average of $6.28 ($6.00–$6.55) across 2 trades over 2025-07-22 to 2025-07-23.
Lite Strategy, Inc. (LITS), formerly MEI Pharma, now focuses on Litecoin as a treasury reserve asset. By fiscal 2026, it accumulated 832,716 Litecoin tokens and operates debt-free. The company's strategy includes active treasury management, share repurchases, and investments in the Litecoin ecosystem. Management aims to increase Litecoin backing per share, but investors face volatility and valuation questions due to mark-to-market accounting and regulatory risks.
Lite Strategy (NASDAQ: LITS) reported a Q4 loss of $0.38 per share, a 5% improvement from $0.40 per share in the prior year. The company did not disclose other financial metrics. The loss reduction indicates slight progress in financial performance.
Lite Strategy, Inc. reported a net loss of $71.2M for FY 2026, worsening from a $15.9M loss in FY 2025, with no revenue in either year. The company pivoted to Litecoin (LTC) as its primary reserve strategy, discontinuing oncology programs and focusing on non-oncologic R&D. Management initiated share repurchases and a covered call options program to manage capital and LTC exposure.
Lite Strategy, Inc. (LITS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share Lite Strategy Buys Back Roughly 4.9 Million Shares at an Average Price of $1.11 with No Debt Incurred SAN DIEGO, July 30, 2026 — Lite Strategy, Inc. (Nasdaq: LITS) (“Lite Str
Flynn James P purchased 25,000 shares of Lite Strategy, Inc. (LITS) at $0.86 on 2026-06-24.
Director James Flynn recently acquired 70,000 shares of Lite Strategy (NASDAQ:LITS) for $98,000, significantly increasing his direct ownership. This purchase occurred shortly after the company authorized a $25 million share buyback program, suggesting management views the stock as undervalued. Lite Strategy shares are currently trading around $1.41, with a market capitalization of $51.86 million, and analysts generally rate the stock as a "Sell".